Wall Street says there are three stocks to buy in October that might rise more than 40% in the next twelve months. Let’s take a look.
BioNTech
So far this year, BioNTech has performed terribly. Due primarily to decreased sales of the COVID-19 vaccine that it co-markets with Pfizer, the biotech stock has dropped more than 30%. But Wall Street is still interested in BioNTech. The average price objective analysts set indicates a 56% potential upside. Admittedly, not all analysts have a very positive outlook on BioNTech. Refinitiv surveyed 17 analysts in August, and seven of them recommended buying the stock, while four others recommended it as a strong buy.
A COVID-19 comeback might increase BioNTech’s vaccine sales in autumn and winter. However, the company’s plans are the primary justification for considering an early purchase. The firm and Pfizer collaborated once more to create a seasonal flu vaccine currently undergoing late-stage testing. There are numerous intriguing investigational treatments within its pipeline in phase 1 and phase 2 clinical trials.
PayPal Enterprises
PayPal Holdings has lost its momentum from earlier in 2023. Thus far this year, the fintech stock has dropped by about 20%. Additionally, that decrease follows a 62% fall in 2022. Wall Street believes that PayPal is about to see a significant comeback. The stock’s consensus price objective is 48% higher than its current share price.
After its massive sell-off, PayPal looks to be extremely inexpensive. Just 10.1 times the estimated earnings are being paid for shares. When growth is considered, the valuation becomes even more appealing, with a ridiculously low price-to-earnings-to-growth ratio of 0.48. You may assume that PayPal would be having financial difficulties given its poor stock performance and ridiculously low valuation, but it isn’t. In Q2, the company’s revenue increased by 8% annually. After-tax earnings per share increased by 24%. PayPal has projected non-GAAP earnings-per-share growth of approximately 20% for the entire year.
Brookfield Infrastructure
Not too long ago, Brookfield Infrastructure was experiencing great success. Units of the limited partnership owned by the corporation had increased by more than 20% year to date by mid-July. However, Brookfield Infrastructure’s Q2 earnings disappointed investors, which made those gains disappear. Still, Wall Street is not lacking in enthusiasm for Brookfield Infrastructure. Over 40% more is currently invested in the LP than is the consensus 12-month price objective. Analysts, as negative as they come, believe Brookfield Infrastructure might increase by 17% which may make it a great time to buy.
A diverse portfolio of infrastructure assets, comprising toll roads, data centres, rail, and cell towers, is possessed by Brookfield Infrastructure. The business should be able to maintain its strong track record of long-term returns by reinvesting its earnings in new ventures. Income investors are likely to be very fond of the stock. For the past 14 years, Brookfield Infrastructures has expanded its distribution. Given that the company’s payout ratio of 68% is appropriate, more rises are probably in the works. At now, the distribution yield of the leader in infrastructure surpasses 5.2%.
Contact Medallion Guarantee on 0203 985 9551.